Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced BRCAvantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states.
Quest Diagnostics Introduces BRCAvantage Plus, Providing New Choices in Genetic Breast Cancer Risk Testing
CompanionDx Reference Lab, LLC, a high-complexity CLIA-certified laboratory specializing in pharmacogenomics, cancer companion diagnostics and targeted next-generation sequencing (NGS), recently announced it is offering a series of NGS-based assays related to cancer. To enable efficient and compliant clinical reporting from NGS, CompanionDx chose to partner with GenomOncology, an Ohio-based genomics technology and services provider.
Caris Life Sciences Study Shows Molecular Profiling May Expand Use of PD-1 and PD-L1 Inhibitors to Wide Variety of Cancers
Caris Life Sciences, a biosciences company focused on fulfilling the promise of precision medicine, recently announced the publication of a study in which Caris Molecular Intelligence™, the company’s panomic, comprehensive tumor profiling service, demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins – the programmed cell death protein 1 (PD-1) and its ligand, PD-L1 – in a substantial proportion of solid tumors. The study results, published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, may expand the use of PD-1 and PD-L1 inhibitors, a new class of anticancer drugs, to a wide variety of solid tumors, including some aggressive subtypes that lack targeted treatment regimens.
bioTheranostics’ Breast Cancer Index Genomic Test Selected as Finalist in 27th Annual CONNECT Most Innovative New Product Awards
bioTheranostics, Inc., a leading genomic solutions provider for cancer, recently announced that its Breast Cancer Index molecular test has been selected as a finalist in the Life Sciences—Diagnostics & Research Tools category for the 2014 Most Innovative New Product Awards, sponsored by CONNECT. CONNECT, a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County, continues its 27-year tradition of honoring San Diego’s leaders of innovation and groundbreaking new products with the annual award.
Human Longevity, Inc. Signs Collaborative Agreement with King’s College London to Access TwinsUK Registry
Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, recently announced a collaborative agreement with King’s College London to access their TwinsUK Registry.